Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

被引：0
|
作者：
Jiri Minarik
Tomas Pika
Jakub Radocha
Alexandra Jungova
Jan Straub
Tomas Jelinek
Ludek Pour
Petr Pavlicek
Martin Mistrik
Lucie Brozova
Petra Krhovska
Katerina Machalkova
Pavel Jindra
Ivan Spicka
Hana Plonkova
Martin Stork
Jaroslav Bacovsky
Lenka Capkova
Michal Sykora
Petr Kessler
Lukas Stejskal
Adriana Heindorfer
Jana Ullrychova
Tomas Skacel
Vladimir Maisnar
Roman Hajek
机构：
[1] Palacky University Olomouc and University Hospital Olomouc,Department of Hemato
[2] Faculty Hospital and Charles University in Hradec Kralove,Oncology, Faculty of Medicine and Dentistry
[3] Charles University Hospital Pilsen,4th Department of Internal Medicine – Hematology
[4] First Faculty of Medicine and General Teaching Hospital Charles University,Hematology and Oncology Department
[5] University Hospital Ostrava and Faculty of Medicine University of Ostrava,1st Medical Department – Clinical Department of Haematology
[6] University Hospital Brno and Faculty of Medicine Masaryk University,Department of Hematooncology
[7] Charles University and Faculty Hospital Kralovske Vinohrady,Department of Internal Medicine, Hematology and Oncology
[8] University Hospital Bratislava,Department of Internal Medicine and Hematology, 3rd Faculty of Medicine
[9] Institute of Biostatistics and Analyses,Department of Hematology and Transfusiology, Faculty of Medicine
[10] Ltd.,Department of Clinical Hematology
[11] Hospital Ceske Budejovice,Department of Hematology and Transfusion Medicine
[12] Hospital Pelhrimov,Department of Hematology
[13] Silesian Hospital in Opava,Department of Hematology
[14] Hospital Liberec,Department of Clinical Hematology
[15] Regional Health Corporation,1st Department of Medicine, First Faculty of Medicine
[16] Masaryk Hospital in Usti nad Labem,undefined
[17] Charles University and General Hospital in Prague,undefined
[18] Millennium Pharmaceuticals,undefined
[19] Inc.,undefined
[20] a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,undefined
来源：
BMC Cancer | / 21卷
关键词：
Multiple myeloma; Ixazomib; Lenalidomide; Dexamethasone; Clinical trial; Patient registry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Skacel, Tomas
    Maisnar, Vladimir
    Hajek, Roman
    [J]. BMC CANCER, 2021, 21 (01)
  • [2] Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
    Hajek, Roman
    Minarik, Jiri
    Straub, Jan
    Pour, Ludek
    Jungova, Alexandra
    Berdeja, Jesus G.
    Boccadoro, Mario
    Brozova, Lucie
    Spencer, Andrew
    Rhee, Frits van
    Vela-Ojeda, Jorge
    Thompson, Michael A.
    Abonour, Rafat
    Chari, Ajai
    Cook, Gordon
    Costello, Caitlin L.
    Davies, Faith E.
    Hungria, Vania T. M.
    Lee, Hans C.
    Leleu, Xavier
    Puig, Noemi
    Rifkin, Robert M.
    Terpos, Evangelos
    Usmani, Saad Z.
    Weisel, Katja C.
    Zonder, Jeffrey A.
    Barinova, Magda
    Kuhn, Matyas
    Silar, Jiri
    Capkova, Lenka
    Galvez, Kenny
    Lu, Jin
    Elliott, Jennifer
    Stull, Dawn Marie
    Ren, Kaili
    Maisnar, Vladimir
    [J]. FUTURE ONCOLOGY, 2021, 17 (19) : 2499 - 2512
  • [3] Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Skacel, Tomas
    Maisnar, Vladimir
    Hajek, Roman
    [J]. BLOOD, 2019, 134
  • [4] Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice
    Schwarzer, A.
    Fruehauf, S.
    Knigsmann, M.
    Schnell, R.
    Reeb, M.
    Heits, F.
    Tirier, C.
    Prange-Krex, G.
    Knauf, W.
    Bachinger, A.
    Weiligmann, C.
    Hoppe, G.
    Glasmacher, A.
    Schmidt, B.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 291 - 291
  • [5] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
  • [6] Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma
    Sokol, Juraj
    Guman, Tomas
    Chudej, Juraj
    Hlebaskova, Monika
    Stecova, Natalia
    Valekova, Lubica
    Kucerikova, Monika
    Stasko, Jan
    [J]. ANNALS OF HEMATOLOGY, 2022, 101 (01) : 81 - 89
  • [7] INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice
    Leleu, Xavier
    Lee, Hans C.
    Zonder, Jeffrey A.
    Macro, Margaret
    Ramasamy, Karthik
    Hulin, Cyrille
    Silar, Jiri
    Kuhn, Matyas
    Ren, Kaili
    Bent-Ennakhil, Nawal
    Cherepanov, Dasha
    Stull, Dawn Marie
    Terpos, Evangelos
    [J]. FUTURE ONCOLOGY, 2024, 20 (14) : 935 - 950
  • [8] Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma
    Juraj Sokol
    Tomas Guman
    Juraj Chudej
    Monika Hlebaskova
    Natalia Stecova
    Lubica Valekova
    Monika Kucerikova
    Jan Stasko
    [J]. Annals of Hematology, 2022, 101 : 81 - 89
  • [9] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    [J]. HAEMATOLOGICA, 2017, 102 : 786 - 787
  • [10] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
12345